Cotellic is a kinase inhibitor indicated for the treatment of patients with BRAF V600E or BRAF V600K mutation-positive advanced melanoma, in combination with vemurafenib. Cotellic selectively blocks the activity of MEK, a cellular protein that is part of the mitogen activated protein kinase (MAPK) signalling pathway, an important cascade of signalling proteins in cells that regulates cellular growth and survival.
Cotellic in combination with Zelboraf is approved in more than 75 countries for use in the same indication, and has been used to treat more than 12,500 patients worldwide. Cotellic was discovered by Exelixis and is being developed by Genentech, a member of the Roche Group, in collaboration with Exelixis.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.